RxDoctor Payments Data

Stephanie Becker, MD

Ophthalmology · Hicksville, NYNPI 1477630390

Payments from drug & device makers

$63,306in general payments, 2019–2025

Across 577 payments — averaging $109.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shire North American Group Inc$22K
  • Sun Pharmaceutical Industries Inc.$17K
  • Novartis$14K
  • AbbVie$2K
  • Vertical Pharmaceuticals, LLC$2K
  • Alcon$1K
  • plus $5K from 27 others

What the payments were for

  • Consulting fees$2,1503%
  • Speaking & faculty fees$41,61566%
  • Travel & lodging$8,28813%
  • Food & beverage$11,02717%
  • Education$2260%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$63,306 in reported general payments places this provider in the 90th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$842,293
Medicare patients
1,129
Services billed
10,408

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine405$552,742
LumiganBimatoprost511$284,831
XiidraLifitegrast110$154,214
XdemvyLotilaner40$68,960
MieboPerfluorohexyloctane/Pf80$64,631
Cyclosporine127$60,094
TyrvayaVarenicline Tartrate42$29,100
SimbrinzaBrinzolamide/Brimonidine Tart81$22,505
CequaCyclosporine17$19,495
Alphagan PBrimonidine Tartrate32$14,491
RocklatanNetarsudil Mesylat/Latanoprost24$12,274
CombiganBrimonidine Tartrate/Timolol39$12,248
VevyeCyclosporine13$11,759
RhopressaNetarsudil Mesylate23$9,215
Travoprost33$8,349

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P, Combigan$2,360$864,312987 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$409$218,844190 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$372$68,96040 claims
AlconSimbrinza, Azopt$1,296$30,76098 claims
Oyster Point Pharma, Inc.Tyrvaya$447$29,10042 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$238$21,48847 claims
Sun Pharmaceutical Industries Inc.Cequa$16,513$19,49517 claims
Harrow Eye, LLCVevye$159$11,75913 claims
Eyevance Pharmaceuticals LLCTobradex St$196$6,53129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Hicksville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →